MOLCURE
Kanagawa, JapanWebsite
An AI-driven drug discovery company that combines next-generation sequencing and robotic automation to discover novel antibody therapeutics.
Loading company information...
An AI-driven drug discovery company that combines next-generation sequencing and robotic automation to discover novel antibody therapeutics.
Company context
MOLCURE prompts can include culture, product, and business context from this profile.
Role targeting
Pair this profile with an open role to generate focused behavioral and technical questions.
Answer coaching
Practice responses, get feedback, and refine stories before applying or interviewing.
MOLCURE is a Japanese biotechnology company headquartered in Kawasaki that specializes in AI-driven drug discovery. Founded in 2013 by Ryu Ogawa, the company integrates proprietary artificial intelligence, evolutionary molecular engineering, and laboratory automation to accelerate the development of therapeutic antibodies and peptides. By leveraging a massive internal dataset of over one billion unique molecular entries, MOLCURE provides end-to-end discovery and lead optimization services for pharmaceutical and biotech partners globally.
Vision: To design molecules to fuel human progress. Mission: To use AI-driven molecular design to enable rapid, reliable discovery of ever more effective drugs.
Founded
2013
Headquarters
Kawasaki, Kanagawa, Japan
Employees
11-50
Industry
Biotech
Opportunity to work at the intersection of cutting-edge AI and wet-lab biotechnology.
Direct impact on accelerating the discovery of life-saving cancer therapeutics.
As a small, specialized startup, resources and team size may be limited compared to large pharmaceutical firms.
Funding
Venture-backed
CEO
Ryu Ogawa
High pressure to deliver results in a competitive and rapidly evolving AI-biotech market.